What Happened
- March 20, 2026 marks the nominal expiry date of the main compound patent for semaglutide — the active molecule in blockbuster drugs Ozempic (diabetes) and Wegovy (obesity) made by Danish pharma giant Novo Nordisk.
- In India, Canada, China, Brazil, and several other major markets (collectively covering ~40% of the world's population), the core semaglutide patent has now expired, enabling domestic manufacturers to legally produce generic versions.
- In the United States, patent term extensions and adjustments have pushed effective patent protection to 2031–2032, meaning American patients will not have access to cheaper generics for several more years.
- Indian pharmaceutical companies — several of which are already capable of synthesising GLP-1 receptor agonists — are expected to begin launching generic semaglutide in the Indian market, potentially at a fraction of the current branded price (Ozempic costs approximately $900–1,000 per month in the US; Indian generic pricing could be dramatically lower).
- The patent expiry is seen as a pivotal moment for public health access: GLP-1 drugs like semaglutide have proven efficacy not just for obesity but also for reducing cardiovascular events, chronic kidney disease, and potentially neurodegenerative conditions.
- However, questions remain about whether generic semaglutide will be accessible to India's lower-income population, given that even "affordable" versions may be beyond the reach of those without insurance.
Static Topic Bridges
TRIPS Agreement and Pharmaceutical Patent Protection
The Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, administered by the World Trade Organization (WTO), sets the global minimum standard for intellectual property protection. For pharmaceuticals, TRIPS mandates a minimum 20-year patent term from the date of filing. This 20-year protection is designed to allow innovator companies to recoup research and development investment before generics compete. However, TRIPS also includes important flexibilities for public health — most significantly, the right to grant compulsory licences (without the patent holder's consent) in national emergencies or to address public health needs. The 2001 Doha Declaration on TRIPS and Public Health explicitly reaffirmed these flexibilities after developing countries raised concerns about access to HIV/AIDS medicines. TRIPS Agreement Article 31 governs compulsory licensing at the national level.
- TRIPS Agreement: negotiated in 1994 under Uruguay Round; enforced from 1995; administered by WTO
- Minimum patent term for pharmaceuticals: 20 years from filing date
- Patent term extension (PTE): US, EU, and Japan allow extensions beyond 20 years to compensate for regulatory approval time — reason why US semaglutide protection extends to 2031-2032
- Doha Declaration (2001): reaffirmed developing countries' right to use TRIPS flexibilities for public health
- TRIPS Article 31bis: allows countries to export generics produced under compulsory licence to countries with no manufacturing capacity (added 2017 as permanent amendment)
Connection to this news: Semaglutide's 20-year patent term filed in 2006 technically expired in 2026 in markets without patent extensions — including India. This is TRIPS's intended mechanism operating: innovation rewarded, then generics democratise access.
Compulsory Licensing under Indian Patents Act 1970 (Section 84)
India's Patents Act, 1970 — among the most progressive pharmaceutical patent laws in the world — contains specific provisions that allow compulsory licences to be granted without the patent holder's consent. Section 84 allows any person to apply for a compulsory licence after three years from the date of patent grant, on grounds that: (a) the reasonable requirements of the public with respect to the patented invention are not satisfied, (b) the patented invention is not available to the public at a reasonably affordable price, or (c) the patented invention is not worked in India. Section 3(d) is another pivotal provision: it prevents "evergreening" by requiring that a new form of a known substance (a salt, ester, or new formulation) must demonstrate significantly enhanced efficacy to be patentable — a protection against trivial patent extensions that delay generic entry.
- Section 84, Patents Act 1970: compulsory licence grounds — (a) unmet public need, (b) unaffordable price, (c) not worked in India
- Section 3(d): prevents evergreening; requires enhanced efficacy for new forms of known substances
- India's first compulsory licence: Natco Pharma v. Bayer (2012) for Sorafenib (cancer drug Nexavar); licence granted on affordability grounds — Bayer charged ₹2.8 lakh/month vs. Natco's ₹8,880/month
- Pharmaceutical Patent Applications: India's examination of pharma patents uses Section 3(d) aggressively, resulting in several patent rejections for blockbuster drugs
- Doha Declaration flexibilities: India's use of Section 3(d) and Section 84 is internationally recognised as TRIPS-compliant
Connection to this news: While voluntary generic entry is now legally possible in India following the patent expiry, Section 84 compulsory licensing (and the threat thereof) was historically used to keep drug prices in check even during the patent term. The semaglutide expiry demonstrates the mainstream route — the 20-year TRIPS clock — working as intended.
GLP-1 Receptor Agonists: Mechanism, Applications, and Public Health Significance
Semaglutide belongs to the class of GLP-1 (Glucagon-Like Peptide-1) receptor agonists — drugs that mimic the natural hormone GLP-1, which is released after eating and signals the pancreas to release insulin, slows gastric emptying, and suppresses appetite. Originally developed for type 2 diabetes management (Ozempic), semaglutide was subsequently approved for chronic weight management at higher doses (Wegovy). Clinical trials (SELECT trial, 2023) showed semaglutide reduces major cardiovascular events (heart attacks, strokes) by 20% in overweight patients without diabetes — expanding its medical significance far beyond weight management. India faces a dual burden: approximately 101 million people with diabetes (the largest diabetic population in the world) and growing obesity rates, particularly in urban areas. Affordable semaglutide generics could be transformative for Indian public health.
- GLP-1 mechanism: mimics GLP-1 hormone → stimulates insulin secretion, suppresses glucagon, slows gastric emptying, reduces appetite
- Ozempic: semaglutide 0.5–2mg weekly injection for type 2 diabetes (FDA approved 2017)
- Wegovy: semaglutide 2.4mg weekly injection for chronic obesity (FDA approved 2021)
- Rybelsus: oral semaglutide tablet for type 2 diabetes
- SELECT trial (2023): 20% reduction in cardiovascular events in obese patients without diabetes
- India's diabetes burden: ~101 million people with diabetes (IDF Atlas, 2023) — largest in the world
- Branded Ozempic pricing: ~$900–1,000/month in the US; Indian generic pricing expected significantly lower
Connection to this news: For India — with the world's largest diabetic population and rapidly rising obesity — affordable generic semaglutide is a significant public health development. The question of actual accessibility (insurance, public health schemes) will determine whether patent expiry translates into health equity.
Key Facts & Data
- Semaglutide main patent filed: March 20, 2006; 20-year TRIPS term expired: March 20, 2026
- Markets with patent expiry in 2026: India, Canada, China, Brazil, Turkey (collectively ~40% of world population)
- US patent protection: extended to 2031–2032 via Patent Term Extension
- India's first compulsory licence: Natco Pharma for Sorafenib (2012) — price reduced from ₹2.8 lakh to ₹8,880/month
- Section 3(d), Indian Patents Act: prevents evergreening of known substances without enhanced efficacy
- Section 84: compulsory licence after 3 years of patent grant on affordability/public need grounds
- GLP-1 agonist: mimics GLP-1 hormone; Ozempic (diabetes), Wegovy (obesity), Rybelsus (oral diabetes)
- SELECT trial (2023): 20% reduction in cardiovascular events among obese patients
- India's diabetic population: ~101 million (IDF Atlas 2023) — world's largest
- TRIPS Agreement (1994): 20-year minimum patent term; includes Doha Declaration flexibilities for public health